ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Li, Hailing ^a   Peng, Wenhui ^a   Jian, Weixia ^b   Li, Yuanmin ^a   Li, Qi ^a   Li, Weiming ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Fasudil; High glucose; Monocyte chemoattractant protein 1; Vascular cell adhesion molecule 1

Indexed keywords

BETA ACTIN; CELL PROTEIN; FASUDIL; GLUCOSE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P MYPT; PROTEIN ROCKI; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CELL ADHESION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC PATIENT; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MONOCYTE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT; TREATMENT DURATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AGED; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL ADHESION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CHINA; COCULTURE TECHNIQUES; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONOCYTES; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RNA, MESSENGER; SINGLE-BLIND METHOD; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84862187308     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-65     Document Type: Article

References (45)

1. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009, 16(1):94-112. 10.2174/092986709787002853, 19149564.
2. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009, 120(13):1266-1286. 10.1161/CIRCULATIONAHA.108.835223, 2910587, 19786641.
3. Manduteanu I, Voinea M, Antohe F, Dragomir E, Capraru M, Radulescu L, Simionescu M. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 2003, 477(3):269-276. 10.1016/j.ejphar.2003.08.016, 14522366.
4. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994, 8(8):504-512.
5. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999, 398(6729):718-723. 10.1038/19546, 10227295.
6. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009, 58(1):215-226. 10.2337/db08-0762, 2606876, 18840783.
7. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008, 57(3):714-723. 10.2337/db07-1241, 18083785.
8. Bu DX, Rai V, Shen X, Rosario R, Lu Y, D'Agati V, Yan SF, Friedman RA, Nuglozeh E, Schmidt AM. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res 2010, 106(6):1040-1051. 10.1161/CIRCRESAHA.109.201103, 2848909, 20133903.
9. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006, 98(3):322-334. 10.1161/01.RES.0000201960.04223.3c, 16484628.
10. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol 2006, 290(3):C661-C668.
11. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, Ganz P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2009, 205(2):517-521. 10.1016/j.atherosclerosis.2008.12.023, 2717178, 19167712.
12. Wu DJ, Xu JZ, Wu YJ, Jean-Charles L, Xiao B, Gao PJ, Zhu DL. Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis 2009, 207(1):68-73. 10.1016/j.atherosclerosis.2009.04.025, 19473657.
13. Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, Hoshijima M, Kaibuchi K, Takeshita A. Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 2001, 21(4):548-554. 10.1161/01.ATV.21.4.548, 11304471.
14. Ocaranza MP, Rivera P, Novoa U, Pinto M, Gonzalez L, Chiong M, Lavandero S, Jalil JE. Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. J Hypertens 2011, 29(4):706-715. 10.1097/HJH.0b013e3283440665, 21330937.
15. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008, 20(2):242-248. 10.1016/j.ceb.2008.01.002, 2377343, 18282695.
16. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007, 68(2):126-131. discussion 131-122, 10.1016/j.surneu.2006.10.037, 17586012.
17. Lee YJ, Kang DG, Kim JS, Lee HS. Effect of Buddleja officinalis on high-glucose-induced vascular inflammation in human umbilical vein endothelial cells. Exp Biol Med (Maywood) 2008, 233(6):694-700.
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
19. Li H, Hui Peng W, Tao Cui S, Lei H, Dong Wei Y, Ming Li W, Wei Xu Y. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med 2011, 49(9):1547-1554.
20. Song J, Kost CK, Martin DS. Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway. Cardiovasc Res 2006, 72(3):456-463. 10.1016/j.cardiores.2006.09.007, 17049502.
21. Godsland IF, Pavitt D, Okoturo O, Edwards RJ, Rubens MB, Feher MD, Flather MD, Elkeles RS. Can protein biomarkers provide an index of coronary artery calcification in patients with Type 2 diabetes?. Atherosclerosis 2010, 213(2):570-572. 10.1016/j.atherosclerosis.2010.09.002, 20880528.
22. Jin C, Lu L, Zhang RY, Zhang Q, Ding FH, Chen QJ, Shen WF. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta 2009, 408(1-2):45-49.
23. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, Garancini MP, Ruotolo G, Luzi L, Perseghin G. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 2009, 32(11):2105-2110. 10.2337/dc09-0763, 2768199, 19641159.
24. Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. Curr Opin Lipidol 2003, 14(5):469-475. 10.1097/00041433-200310000-00007, 14501585.
25. Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K, Szabo C, Ceriello A. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004, 2(8):1453-1459. 10.1111/j.1538-7836.2004.00835.x, 15304054.
26. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59(1):249-255. 10.2337/db09-0801, 2797929, 19833897.
27. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007, 293(1):H610-H619. 10.1152/ajpheart.00236.2007, 2228254, 17384130.
28. Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007, 193(2):328-334. 10.1016/j.atherosclerosis.2006.09.016, 17097661.
29. Pagiatakis C, Gordon JW, Ehyai S, McDermott JC. A novel RhoA/ROCK-CPI-17-MEF2C signaling pathway regulates vascular smooth muscle cell gene expression. J Biol Chem 2012, 287(11):8361-8370. 10.1074/jbc.M111.286203, 22275376.
30. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003, 93(8):767-775. 10.1161/01.RES.0000096650.91688.28, 14500337.
31. Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K. High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol 2012, 11(1):28. 10.1186/1475-2840-11-28, 3350454, 22436066.
32. Wang J, Liu H, Chen B, Li Q, Huang X, Wang L, Guo X, Huang Q. RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc Diabetol 2012, 11:7. 10.1186/1475-2840-11-7, 3280169, 22251897.
33. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008, 118(5):1632-1644. 10.1172/JCI29226, 2293333, 18414683.
34. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, Takeya M, Yoshimura T, Takeshita A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38(1):100-104. 10.1161/01.HYP.38.1.100, 11463768.
35. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, Shimokawa H, Takeshita A. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001, 21(5):868-873. 10.1161/01.ATV.21.5.868, 11348889.
36. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003, 113(3):329-342. 10.1016/S0092-8674(03)00278-2, 12732141.
37. Ishiko K, Sakoda T, Akagami T, Naka T, Doi T, Tsujino T, Masuyama T, Ohyanagi M. Hyperglycemia induced cell growth and gene expression via the serum response element through RhoA and Rho-kinase in vascular smooth muscle cells. Prep Biochem Biotechnol 2010, 40(2):139-151. 10.1080/10826060903558927, 20213575.
38. Kawamura H, Yokote K, Asaumi S, Kobayashi K, Fujimoto M, Maezawa Y, Saito Y, Mori S. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004, 24(2):276-281.
39. Matsumoto A, Manthey HD, Marsh SA, Fassett RG, de Haan JB, Rolfe BE, Coombes JS. Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE(-/-) mice. Int J Cardiol 2012, . doi:10.1016/j.ijcard.2012.03.172.
40. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002, 22(2):146-167. 10.1002/med.10001, 11857637.
41. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003, 278(39):37459-37464. 10.1074/jbc.M305877200, 12878595.
42. Videm V, Albrigtsen M. Soluble ICAM-1 and VCAM-1 as markers of endothelial activation. Scand J Immunol 2008, 67(5):523-531. 10.1111/j.1365-3083.2008.02029.x, 18363595.
43. Postadzhiyan AS, Tzontcheva AV, Kehayov I, Finkov B. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes. Clin Biochem 2008, 41(3):126-133. 10.1016/j.clinbiochem.2007.09.001, 18061588.
44. Landsberger M, Wolff B, Jantzen F, Rosenstengel C, Vogelgesang D, Staudt A, Dahm JB, Felix SB. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 2007, 190(1):43-52. 10.1016/j.atherosclerosis.2006.02.009, 16529752.
45. Kojima Y, Ishida T, Sun L, Yasuda T, Toh R, Rikitake Y, Fukuda A, Kume N, Koshiyama H, Taniguchi A, et al. Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo. Cardiovasc Res 2010, 87(2):385-393. 10.1093/cvr/cvp419, 20045866.